{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:20Z","timestamp":1790612120262,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201900007C"],"award-info":[{"award-number":["HHSO100201900007C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["75A50122C00080."],"award-info":[{"award-number":["75A50122C00080."]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40265-024-02082-9","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T14:02:46Z","timestamp":1725026566000},"page":"1219-1250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Cefepime\u2013Taniborbactam: A Novel Cephalosporin\/\u03b2-Lactamase Inhibitor Combination"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3238-0082","authenticated-orcid":false,"given":"George G.","family":"Zhanel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Mikolayanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney K.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Zelenitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyel","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denice","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lagac\u00e9-Wiens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Walkty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"1","key":"2082_CR1","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S1473-3099(20)30868-9","volume":"22","author":"MF Mojica","year":"2022","unstructured":"Mojica MF, Rossi M-A, Vila AJ, Bonomo RA. The urgent need for metallo-\u03b2-lactamase inhibitors: an unattended global threat. Lancet. 2022;22(1):e28\u201334.","journal-title":"Lancet"},{"issue":"6","key":"2082_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/QCO.0000000000000885","volume":"35","author":"R Arya","year":"2022","unstructured":"Arya R, Goldner BS, Shorr AF. Novel agents in development for multidrug-resistant Gram-negative infections: potential new options facing multiple challenges. Curr Opin Infect Dis. 2022;35(6):589\u201394.","journal-title":"Curr Opin Infect Dis"},{"issue":"6","key":"2082_CR3","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1021\/acs.jmedchem.9b01518","volume":"63","author":"B Liu","year":"2020","unstructured":"Liu B, Trout REL, Chu GH, Mcgarry D, Jackson RW, Hamrick JC, et al. Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-\u03b2-lactamase inhibitor for carbapenem-resistant bacterial infections. J Med Chem. 2020;63(6):2789\u2013801.","journal-title":"J Med Chem"},{"issue":"6","key":"2082_CR4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3390\/biom10060899","volume":"10","author":"PA Lang","year":"2020","unstructured":"Lang PA, Parkova A, Leissing TM, Calvopi\u00f1a K, Cain R, Krajnc A, et al. Bicyclic boronates as potent inhibitors of AmpC, the class C \u03b2-lactamase from Escherichia coli. Biomolecules. 2020;10(6):899.","journal-title":"Biomolecules"},{"issue":"11","key":"2082_CR5","doi-asserted-by":"publisher","first-page":"e00440","DOI":"10.1128\/aac.00440-23","volume":"67","author":"O Lomovskaya","year":"2023","unstructured":"Lomovskaya O, Castanheira M, Lindley J, Rubio-Aparicio D, Nelson K, Tsivkovski R, et al. In vitro potency of xeruborbactam in combination with multiple \u03b2-lactam antibiotics in comparison with other \u03b2-lactam\/\u03b2-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum \u03b2-lactamase-producing Enterobacterales. Antimicrob Agents Chemother. 2023;67(11):e00440-e523.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2082_CR6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/jac\/dkaa511","volume":"76","author":"B Isler","year":"2021","unstructured":"Isler B, Harris P, Stewart AG, Paterson DL. An update on cefepime and its future role in combination with novel \u03b2-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. J Antimicrob Chemother. 2021;76(3):550\u201360.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2082_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/QCO.0000000000000984","volume":"36","author":"M Bassetti","year":"2023","unstructured":"Bassetti M, Castaldo N, Fantin A, Giacobbe DR, Vena A. Antibiotic therapy for nonfermenting Gram-negative bacilli infections: future perspectives. Curr Opin Infect Dis. 2023;36(6):615\u201322.","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"2082_CR8","doi-asserted-by":"publisher","first-page":"e01281","DOI":"10.1128\/aac.01281-22","volume":"67","author":"JA Karlowsky","year":"2023","unstructured":"Karlowsky JA, Hackel MA, Wise MG, Six DA, Uehara T, Daigle DM, et al. In vitro activity of cefepime\u2013taniborbactam and comparators against clinical isolates of Gram-negative bacilli from 2018 to 2020: results from the global evaluation of antimicrobial resistance via surveillance (GEARS) program. Antimicrob Agents Chemother. 2023;67(1):e01281-e1322.","journal-title":"Antimicrob Agents Chemother"},{"key":"2082_CR9","doi-asserted-by":"crossref","unstructured":"Wise M, Hackel M, Sahm D. In vitro activity of cefepime\u2013taniborbactam and comparators against genotypically characterized carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) from the United States, 2018\u20132021 [abstract no. 1527470 plus poster]. IDweek; 11\u201315 October 2023: Boston, MA.","DOI":"10.1093\/ofid\/ofad500.1773"},{"issue":"3","key":"2082_CR10","doi-asserted-by":"publisher","first-page":"e01963","DOI":"10.1128\/AAC.01963-19","volume":"64","author":"JC Hamrick","year":"2020","unstructured":"Hamrick JC, Docquier J-D, Uehara T, Myers CL, Six DA, Chatwin CL, et al. VNRX-5133 (taniborbactam), a broad-spectrum inhibitor of serine-and metallo-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2020;64(3):e01963-e2019.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2082_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/antibiotics12040761","volume":"12","author":"M Karvouniaris","year":"2023","unstructured":"Karvouniaris M, Almyroudi MP, Abdul-Aziz MH, Blot S, Paramythiotou E, Tsigou E, et al. Novel antimicrobial agents for Gram-negative pathogens. Antibiotics. 2023;12(4):761.","journal-title":"Antibiotics"},{"issue":"5","key":"2082_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/antibiotics11050579","volume":"11","author":"AR Losito","year":"2022","unstructured":"Losito AR, Raffaelli F, Del Giacomo P, Tumbarello M. New drugs for the treatment of Pseudomonas aeruginosa infections with limited treatment options: a narrative review. Antibiotics. 2022;11(5):579.","journal-title":"Antibiotics"},{"issue":"3","key":"2082_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/14787210.2024.2303028","volume":"22","author":"NA Mackow","year":"2024","unstructured":"Mackow NA, Van Duin D. Reviewing novel treatment options for carbapenem-resistant Enterobacterales. Expert Rev Anti Infect Ther. 2024;22(3):71\u201385.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"7","key":"2082_CR14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa2304748","volume":"390","author":"FM Wagenlehner","year":"2024","unstructured":"Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, et al. Cefepime\u2013taniborbactam in complicated urinary tract infection. N Eng J Med. 2024;390(7):611\u201322.","journal-title":"N Eng J Med"},{"key":"2082_CR15","unstructured":"BusinessWire Press Release. Venatorx and Melinta provide update on status of US new drug application for cefepime\u2013taniborbactam. 2024. https:\/\/venatorx.com\/press-releases\/venatorx-and-melinta-provide-update-on-status-of-u-s-new-drug-application-for-cefepime-taniborbactam\/. Accessed 8 Apr 2024."},{"key":"2082_CR16","first-page":"1","volume":"2022","author":"KO Al","year":"2022","unstructured":"Al KO. Review on characterization, properties, and analytical methods of cefepime. Int J Anal Chem. 2022;2022:1\u201310.","journal-title":"Int J Anal Chem."},{"issue":"18","key":"2082_CR17","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1016\/j.jmb.2019.04.002","volume":"431","author":"CL Tooke","year":"2019","unstructured":"Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi Y, et al. \u03b2-Lactamases and \u03b2-lactamase inhibitors in the 21st century. J Mol Biol. 2019;431(18):3472\u2013500.","journal-title":"J Mol Biol"},{"issue":"6","key":"2082_CR18","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1586\/14787210.6.6.805","volume":"6","author":"A Endimiani","year":"2008","unstructured":"Endimiani A, Perez F, Bonomo RA. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther. 2008;6(6):805\u201324.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"18","key":"2082_CR19","doi-asserted-by":"publisher","first-page":"8544","DOI":"10.1021\/acs.jmedchem.9b00911","volume":"62","author":"A Krajnc","year":"2019","unstructured":"Krajnc A, Brem J, Hinchliffe P, Calvopi\u00f1a K, Panduwawala TD, Lang PA, et al. Bicyclic boronate VNRX-5133 inhibits metallo- and serine-\u03b2-lactamases. J Med Chem. 2019;62(18):8544\u201356.","journal-title":"J Med Chem"},{"issue":"8","key":"2082_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025247","volume":"6","author":"K Bush","year":"2016","unstructured":"Bush K, Bradford PA. \u03b2-lactams and \u03b2-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6(8): a025247.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"2082_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","volume":"78","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, et al. Imipenem\u2013relebactam and meropenem\u2013vaborbactam: two novel carbapenem-\u03b2-lactamase inhibitor combinations. Drugs. 2018;78(1):65\u201398.","journal-title":"Drugs"},{"key":"2082_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01168-23","author":"SI Drusin","year":"2023","unstructured":"Drusin SI, Le Terrier C, Poirel L, Bonomo RA, Vila AJ, Moreno DM. Structural basis of metallo-\u03b2-lactamase resistance to taniborbactam. Antimicrob Agents Chemother. 2023. https:\/\/doi.org\/10.1128\/aac.01168-23.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2082_CR23","doi-asserted-by":"publisher","first-page":"e00918","DOI":"10.1128\/Spectrum.00918-21","volume":"9","author":"EJ Roach","year":"2021","unstructured":"Roach EJ, Uehara T, Daigle DM, Six DA, Khursigara CM. The next-generation \u03b2-lactamase inhibitor taniborbactam restores the morphological effects of cefepime in KPC-producing Escherichia coli. Microbiol Spectr. 2021;9(2):e00918-e921.","journal-title":"Microbiol Spectr."},{"issue":"10","key":"2082_CR24","doi-asserted-by":"publisher","first-page":"e00397","DOI":"10.1128\/AAC.00397-20","volume":"64","author":"SE Boyd","year":"2020","unstructured":"Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo-\u03b2-lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother. 2020;64(10):e00397-e420.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2082_CR25","doi-asserted-by":"publisher","first-page":"e01332","DOI":"10.1128\/aac.01332-23","volume":"68","author":"D Ono","year":"2024","unstructured":"Ono D, Mojica MF, Bethel CR, Ishii Y, Drusin SI, Moreno DM, et al. Structural role of K224 in taniborbactam inhibition of NDM-1. Antimicrob Agents Chemother. 2024;68(2):e01332-e1423.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2082_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10096-023-04697-4","volume":"43","author":"M Hern\u00e1ndez-Garc\u00eda","year":"2024","unstructured":"Hern\u00e1ndez-Garc\u00eda M, Garc\u00eda-Castillo M, Nieto-Torres M, Bou G, Ocampo-Sosa A, Pitart C, et al. Deciphering mechanisms affecting cefepime\u2013taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain. Eur J Clin Microbiol Infect Dis. 2024;43(2):279\u201396.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"2082_CR27","doi-asserted-by":"publisher","first-page":"dlab197","DOI":"10.1093\/jacamr\/dlab197","volume":"4","author":"AR Golden","year":"2022","unstructured":"Golden AR, Baxter MR, Karlowsky JA, Mataseje L, Mulvey MR, Walkty A, et al. Activity of cefepime\/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007\u201319. JAC Antimicrob Resist. 2022;4(1):dlab197.","journal-title":"JAC Antimicrob Resist"},{"issue":"4","key":"2082_CR28","doi-asserted-by":"publisher","first-page":"e02179","DOI":"10.1128\/aac.02179-21","volume":"66","author":"N Satapoomin","year":"2022","unstructured":"Satapoomin N, Dulyayangkul P, Avison MB. Klebsiella pneumoniae mutants resistant to ceftazidime-avibactam plus aztreonam, imipenem-relebactam, meropenem-vaborbactam, and cefepime\u2013taniborbactam. Antimicrob Agents Chemother. 2022;66(4):e02179-e2221.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2082_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01118-23","volume":"14","author":"AM Hujer","year":"2023","unstructured":"Hujer AM, Marshall SH, Mack AR, Hujer KM, Bakthavatchalam YD, Umarkar K, et al. Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through \u03b2-lactam-enhancer-mechanism-based cefepime\/zidebactam. MBio. 2023;14(6): e01118.","journal-title":"MBio"},{"issue":"1","key":"2082_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/jac\/dkaa391","volume":"76","author":"S Mushtaq","year":"2021","unstructured":"Mushtaq S, Vickers A, Doumith M, Ellington MJ, Woodford N, Livermore DM. Activity of \u03b2 -lactam\/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2021;76(1):160\u201370.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2082_CR31","doi-asserted-by":"publisher","first-page":"e00203","DOI":"10.1128\/AAC.00203-21","volume":"65","author":"M Zalacain","year":"2021","unstructured":"Zalacain M, Lozano C, Llanos A, Sprynski N, Valmont T, De Piano C, et al. Novel specific metallo- \u03b2-lactamase inhibitor ANT2681 restores meropenem activity to clinically effective levels against NDM-positive Enterobacterales. Antimicrob Agents Chemother. 2021;65(6):e00203-e221.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2082_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10096-023-04732-4","volume":"43","author":"C Le Terrier","year":"2024","unstructured":"Le Terrier C, Freire S, Nordmann P, Poirel L. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility\/resistance to cefiderocol: which are the best present and future therapeutic alternatives? Eur J Clin Microbiol Infect Dis. 2024;43(2):339\u201354.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2082_CR33","unstructured":"Zeiser, E, Becka SA, LiPuma JJ, Six DA, Moeck G, Papp-Wallace KM. Examining the antimicrobial activity of cefepime\u2013taniborbactam (formerly cefepime\/VNRX-5133) against Burkholderia species isolated from cystic fibrosis patients in the United States [abstract no. 02144 plus poster]. 31st European Congress of Clinical Microbiology and Infectious Diseases; Virtual Conference, Online; 2021."},{"key":"2082_CR34","unstructured":"Wise M, Hackel M, Sahm D. In vitro activity of cefepime\u2013taniborbactam against molecularly characterized Enterobacterales and P. aeruginosa collected worldwide from 2018-2020. [abstract no. 01658 plus poster]. 32nd European Congress of Clinical Microbiology and Infectious Diseases; Virtual Conference, Online; 2022."},{"key":"2082_CR35","doi-asserted-by":"crossref","unstructured":"Wise M, Hackel M, Sahm D. In vitro activity of cefepime\u2013taniborbactam and comparators against a global collection of carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) with and without carbapenemases [abstract no. 1710 plus poster]. IDweek; 19\u201323 Oct 2022: Washington, DC.","DOI":"10.1093\/ofid\/ofac492.1340"},{"key":"2082_CR36","unstructured":"Niccolai C, Antonelli A, Benvenuti F, Zenoni A, Aiezza N, Baccani I, et al. Activity of cefepime\u2013taniborbactam (formerly cefepime\/VNRX-5133) and comparators against NDM-producing Enterobacterales from a regional outbreak. 31st European Congress of Clinical Microbiology and Infectious Diseases; Virtual Conference, Online; 2021."},{"key":"2082_CR37","doi-asserted-by":"crossref","unstructured":"Hackel M, Wise M, Sahm D. Antimicrobial activity of cefepime in combination with taniborbactam (formerly VNRX-5133) against a European 2018-2020 surveillance collection of Pseudomonas aeruginosa [abstract no. 02564 plus poster]. 31st European Congress of Clinical Microbiology and Infectious Diseases; Virtual Conference, Online; 2021.","DOI":"10.1093\/ofid\/ofab466.203"},{"key":"2082_CR38","unstructured":"CLSI. Performance standards for antimicrobial susceptibility testing-thirty-Fourth Edition: M100. 2024."},{"issue":"7","key":"2082_CR39","doi-asserted-by":"publisher","first-page":"e00339","DOI":"10.1128\/aac.00339-23","volume":"67","author":"C Le Terrier","year":"2023","unstructured":"Le Terrier C, Nordmann P, Freret C, Seigneur M, Poirel L. Impact of acquired broad spectrum \u03b2 -lactamases on susceptibility to novel combinations made of \u03b2-lactams (aztreonam, cefepime, meropenem, and imipenem) and novel \u03b2-lactamase inhibitors in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2023;67(7):e00339-e423.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2082_CR40","doi-asserted-by":"publisher","first-page":"e00991","DOI":"10.1128\/aac.00991-23","volume":"68","author":"C Le Terrier","year":"2024","unstructured":"Le Terrier C, Viguier C, Nordmann P, Vila AJ, Poirel L. Relative inhibitory activities of the broad-spectrum \u03b2-lactamase inhibitor taniborbactam against metallo-\u03b2-lactamases. Antimicrob Agents Chemother. 2024;68(2):e00991-e1023.","journal-title":"Antimicrob Agents Chemother"},{"key":"2082_CR41","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/jac\/dkad061","volume":"78","author":"C Le Terrier","year":"2023","unstructured":"Le Terrier C, Nordmann P, Sadek M, Poirel L. In vitro activity of cefepime\/zidebactam and cefepime\/taniborbactam against aztreonam\/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates. J Antimicrob Chemother. 2023;78:1191\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"2082_CR42","unstructured":"Zeiser, E, Six D, Moeck G, Papp-Wallace K. Cefepime\u2013taniborbactam (formerly cefepime\/VNRX-5133) demonstrates potent activity vs. Enterobacterales with blaOXA-48. 31st European Congress of Clinical Microbiology and Infectious Diseases; Virtual Conference, Online; 2021."},{"key":"2082_CR43","doi-asserted-by":"crossref","unstructured":"Kline, E, Squires K, Haidar G, Synder G, Harrison L, Van Tyne D, et al. In vitro activity of aztreonam-avibactam, cefiderocol, and cefepime\u2013taniborbactam against multi-species, NDM- producing Enterobacterales causing a local outbreak [abstract no. 2185 plus poster]. IDweek; 11\u201315 Oct 2023: Boston, MA.","DOI":"10.1093\/ofid\/ofad500.1807"},{"issue":"10","key":"2082_CR44","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1093\/jac\/dkac241","volume":"77","author":"C Lasarte-Monterrubio","year":"2022","unstructured":"Lasarte-Monterrubio C, Fraile-Ribot PA, V\u00e1zquez-Ucha JC, Cabot G, Guijarro-S\u00e1nchez P, Alonso-Garc\u00eda I, et al. Activity of cefiderocol, imipenem\/relebactam, cefepime\/taniborbactam and cefepime\/zidebactam against ceftolozane\/tazobactam-and ceftazidime\/avibactam-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2022;77(10):2809\u201315.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2082_CR45","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1128\/AAC.36.3.552","volume":"36","author":"RH Barbhaiya","year":"1992","unstructured":"Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother. 1992;36(3):552\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2082_CR46","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1128\/AAC.41.8.1783","volume":"41","author":"MD Reed","year":"1997","unstructured":"Reed MD, Yamashita TS, Knupp CK, Veazey JM, Blumer JL. Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children. Antimicrob Agents Chemother. 1997;41(8):1783\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2082_CR47","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40262-022-01137-y","volume":"61","author":"GM Pais","year":"2022","unstructured":"Pais GM, Chang J, Barreto EF, Stitt G, Downes KJ, Alshaer MH, et al. Clinical pharmacokinetics and pharmacodynamics of cefepime. Clin Pharmacokinet. 2022;61(7):929\u201353.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"2082_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1128\/AAC.27.2.207","volume":"27","author":"RE Kessler","year":"1985","unstructured":"Kessler RE, Bies M, Buck RE, Chisholm DR, Pursiano TA, Tsai YH, et al. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics. Antimicrob Agents Chemother. 1985;27(2):207\u201316.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2082_CR49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1128\/AAC.31.1.55","volume":"31","author":"RH Barbhaiya","year":"1987","unstructured":"Barbhaiya RH, Forgue ST, Shyu WC, Papp EA, Pittman KA. High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine. Antimicrob Agents Chemother. 1987;31(1):55\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2082_CR50","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/FTD.0000000000000675","volume":"42","author":"MH Al-Shaer","year":"2020","unstructured":"Al-Shaer MH, Alghamdi WA, Graham E, Peloquin CA. Meropenem, cefepime, and piperacillin protein binding in patient samples. Ther Drug Monit. 2020;42(1):129\u201332.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"2082_CR51","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1097\/01.CCM.0000069734.38738.C8","volume":"31","author":"E Boselli","year":"2003","unstructured":"Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, et al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med. 2003;31(8):2102\u20136.","journal-title":"Crit Care Med"},{"issue":"3","key":"2082_CR52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.diagmicrobio.2005.09.007","volume":"54","author":"TP Lodise","year":"2006","unstructured":"Lodise TP, Rhoney DH, Tam VH, McKinnon PS, Drusano GL. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagn Microbiol Infect Dis. 2006;54(3):223\u201330.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"2082_CR53","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1128\/AAC.01141-08","volume":"53","author":"AM Nicasio","year":"2009","unstructured":"Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti JL, et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2009;53(4):1476\u201381.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2082_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/aac.02046-21","volume":"66","author":"MH Alshaer","year":"2022","unstructured":"Alshaer MH, Goutelle S, Santevecchi BA, Shoulders BR, Venugopalan V, Cherabuddi K, et al. Cefepime precision dosing tool: from standard to precise dose using nonparametric population pharmacokinetics. Antimicrob Agents Chemother. 2022;66(2):1\u201310.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2082_CR55","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/jac\/dkac447","volume":"78","author":"TE Asempa","year":"2023","unstructured":"Asempa TE, Kuti JL, Nascimento JC, Pope SJ, Salerno EL, Troy PJ, et al. Bronchopulmonary disposition of IV cefepime\/taniborbactam (2\u20130.5 g) administered over 2 h in healthy adult subjects. J Antimicrob Chemother. 2023;78(3):703\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"2082_CR56","doi-asserted-by":"publisher","first-page":"e01053","DOI":"10.1128\/AAC.01053-21","volume":"65","author":"JA Dowell","year":"2021","unstructured":"Dowell JA, Dickerson D, Henkel T. Safety and pharmacokinetics in human volunteers of taniborbactam (VNRX-5133), a novel intravenous \u03b2-lactamase inhibitor. Antimicrob Agents Chemother. 2021;65(11):e01053-e1121.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2082_CR57","doi-asserted-by":"publisher","first-page":"e00253","DOI":"10.1128\/aac.00253-22","volume":"66","author":"JA Dowell","year":"2022","unstructured":"Dowell JA, Marbury TC, Smith WB, Henkel T. Safety and pharmacokinetics of taniborbactam (VNRX-5133) with cefepime in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 2022;66(9):e00253-e322.","journal-title":"Antimicrob Agents Chemother"},{"key":"2082_CR58","unstructured":"Henkel T, Geibel B, Dowell J, Dickerson D. Pharmacokinetics of VNRX-5133 in combination with cefepime and metronidazole [poster no. P1951]. 29th European Congress of Clinical Microbiology and Infectious Diseases; 13\u201316 Apr 2019: Amsterdam."},{"key":"2082_CR59","unstructured":"Noel AR, Bowker KE, Attwood M, MacGowan AP. Pharmacodynamics of VNRX-5133 in combination with cefepime studied in an in vitro model of infection [abstract no. O1601 plus poster]. 29th European Congress of Clinical Microbiology and Infectious Diseases; 13\u201316 Apr 2019: Amsterdam."},{"issue":"12","key":"2082_CR60","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1093\/jac\/dkaa373","volume":"75","author":"K Abdelraouf","year":"2020","unstructured":"Abdelraouf K, Almarzoky Abuhussain S, Nicolau DP. In vivo pharmacodynamics of new-generation \u03b2-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-\u03b2-lactamase-producing Gram-negative bacteria. J Antimicrob Chemother. 2020;75(12):3601\u201310.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2082_CR61","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1093\/jac\/dkac446","volume":"78","author":"K Abdelraouf","year":"2023","unstructured":"Abdelraouf K, Nicolau DP. In vivo pharmacokinetic\/pharmacodynamic evaluation of cefepime\/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model. J Antimicrob Chemother. 2023;78(3):692\u2013702.","journal-title":"J Antimicrob Chemother"},{"key":"2082_CR62","unstructured":"Avery LM, Edwards M, Yi F, Moeck G, Pevear DC. Cefepime\u2013taniborbactam human exposures suppress the emergence of resistance among cefepime-nonsusceptible Enterobacterales and Pseudomonas aeruginosa in a hollow fiber infection model. MAD-ID 2023. Orlando, 2023."},{"key":"2082_CR63","doi-asserted-by":"crossref","unstructured":"Avery LM, Edwards M, Yi F, Sabato PE, Moeck G, Pevear DC. Activities of cefepime\u2013taniborbactam and ceftazidime-avibactam against cefepime-resistant respiratory gram-negative pathogens in a hollow fiber infection model [poster 590]. IDweek; 19\u201323 Oct 2022: Washington, DC.","DOI":"10.1093\/ofid\/ofac492.642"},{"issue":"2","key":"2082_CR64","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/jac\/dkab405","volume":"77","author":"MJ Lasko","year":"2022","unstructured":"Lasko MJ, Nicolau DP, Asempa TE. Clinical exposure-response relationship of cefepime\/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model. J Antimicrob Chemother. 2022;77(2):443\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"2082_CR65","unstructured":"US Food and Drug Administration. Complicated urinary tract infections: developing drugs for treatment. Guidance for industry. 2018. https:\/\/www.fda.gov\/media\/71313\/download. Accessed 15 Apr 2024."},{"issue":"Suppl 2","key":"2082_CR66","doi-asserted-by":"publisher","first-page":"ofad500.2141","DOI":"10.1093\/ofid\/ofad500.2141","volume":"10","author":"G Moeck","year":"2023","unstructured":"Moeck G, Gasink L, Dorr MB, Chen H, Woosley L, Mendes RE, et al. Outcomes by resistance phenotype and genotype among baseline pathogen in patients with complicated urinary tract infection (cUTI) in the Phase 3 CERTAIN-1 study. Open Forum Infect Dis. 2023;10(Suppl 2):ofad500.2141.","journal-title":"Open Forum Infect Dis"},{"key":"2082_CR67","unstructured":"McGovern P. Cefepime\u2013taniborbactam addressing current and future antimicrobial resistance. Venatorx Pharmaceuticals. IDWeek 2022; 19\u201323 Oct 2022: Washington, DC."},{"key":"2082_CR68","unstructured":"Maxipime\u00ae product monograph. Montreal: Bristol-Myers Squibb Canada Inc.; 2008."},{"issue":"1","key":"2082_CR69","doi-asserted-by":"publisher","DOI":"10.15190\/d.2018.1","volume":"6","author":"S Andrei","year":"2018","unstructured":"Andrei S, Valeanu L, Chirvasuta R, Stefan M-G. New FDA approved antibacterial drugs: 2015\u20132017. Discoveries. 2018;6(1): e81.","journal-title":"Discoveries"},{"issue":"6","key":"2082_CR70","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00130-20","volume":"64","author":"R Tsivkovski","year":"2020","unstructured":"Tsivkovski R, Totrov M, Lomovskaya O. Biochemical characterization of QPX7728, a new ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases. Antimicrob Agents Chemother. 2020;64(6): e0013020.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"2082_CR71","doi-asserted-by":"publisher","first-page":"S731","DOI":"10.1093\/ofid\/ofab466.1478","volume":"8","author":"AR Mack","year":"2021","unstructured":"Mack AR, Bethel CR, Taracila MA, Van Den Akker F, Miller BA, Six DA, et al. Taniborbactam inhibits cefepime-hydrolyzing variants of Pseudomonas-derived cephalosporinase (PDC). Open Forum Infect Dis. 2021;8(Suppl. 1):S731\u20132.","journal-title":"Open Forum Infect Dis"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02082-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02082-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02082-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T11:06:50Z","timestamp":1729940810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02082-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2082"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02082-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"31 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"George Zhanel has received research grants from Venatorx; David. Nicolau has received research grants from Venatorx; and Carlo Tascini has received research grants from Venatorx. Celine Mansour, Stacey Mikolayanko, Courtney K. Lawrence, Sheryl Zelenitsky, Danyel Ramirez, Frank Schweizer, Denice Bay, Heather Adam, Philippe Lagac\u00e9-Wiens, Andrew Walkty, Neal Irfan, Nina Clark and James A. Karlowsky have declared no conflicts of interest that may be relevant to the contents of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The work described in this manuscript was funded (in part\/in whole) with federal funds from the US Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR), and Biomedical Advanced Research and Development Authority (BARDA), under contract numbers HHSO100201900007C and 75A50122C00080. The contract and federal funding are not an endorsement of the study results, product or company. The authors are grateful to Dr. Greg Moeck, Dr. Paul McGovern, and Venatorx Pharmaceuticals for their assistance with literature retrieval and an unrestricted research grant to aid in student funding and publication costs.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"GGZ was involved in the design and concept of the entire manuscript and drafting all sections, and also acted as the senior and corresponding author. CM, SM, and JAK were involved in the design and concept of the entire manuscript and drafting all sections. CKL and SZ were involved in the design and concept of the entire manuscript and drafting the Pharmacokinetic and Pharmacodynamic sections. DR and FS were involved in the design and concept of the entire manuscript and drafting the Chemistry and Microbiology sections. DB was involved in the design and concept of the entire manuscript and drafting the Introduction and Mechanism of Action\/Resistance sections. HJA was involved in the design and concept of the entire manuscript and drafting the Microbiology section. PLW was involved in the design and concept of the entire manuscript and drafting the Animal Models section. AW was involved in the design and concept of the entire manuscript and drafting the clinical trials and adverse effects sections. NI was involved in the design and concept of the entire manuscript and drafting the Adverse Effects, Drug Interactions and Place in Therapy sections. NC was involved in the design and concept of the entire manuscript and drafting the Clinical Trials section. DN was involved in the design and concept of the entire manuscript and drafting the Pharmacodynamics section. CT was involved in the design and concept of the entire manuscript and drafting the Place in Therapy section.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contribution"}}]}}